Oncology

Dealing with cancer is challenging enough for patients and providers. But even when their different perspectives are factored in, that’s not the whole story.

Cancer medication spending is unsustainable, but significant savings can be achieved just by reducing waste. Here’s how.

Experts predict what oncology care will look like a decade from now.

A Wamberg Genomic Advisors’ Cancer Survey has revealing findings from people dealing directly with cancer.

As lymphoma treatments become less cookie-cutter and more custom, the Leukemia & Lymphoma Society Chief Medical Officer Gwen Nichols, MD, shares how healthcare executives need to alter their approach to managing therapy regimens to increase cure rates and survivorship.

The ability of an oncology practice to succeed in the OCM varies depending on this key factor, according to Avalere research.

New cancer drugs continue to offer patients hope. Here are eight of them.

This year has been another year full of oncology approvals, proving that the oncology pipeline is robust with first-of-the kind molecules, competitor products for existing agents, and biosimilars.

Ochsner Health System’s brings early-stage clinical trials to the Gulf South region.

Here are the top 3 new approvals from FDA.

New cancer developments and research can be challenging to sort through. Here are four misconceptions about cancer that you should know.

A stepwise approach can be best. Here are seven rules to follow.

Payers struggle to determine the appropriate criteria for covering innovative treatments and providers want to increase patient access. Patients’ lives can hang in the balance.

Onboarding new oncology patients can be a delicate process to help them prepare for their care journey. Here are the first steps.

While promising new options keep entering the scene, high costs can be problematic to patients and healthcare organizations. Here are some ways to cope.

The latest lymphoma research continues to bring new hope for patents, families and care providers. In looking at such advances, here are four things to know.

Cancer is one of the top deadliest diseases in the world and can be difficult to treat. We want to hear from you about your current challenges and what you think about future prospects in cancer therapy.

Medical malpractice companies partner to provide a detailed analysis of breast cancer medical malpractice claims. The findings may surprise you.

Basket trials are designed to test therapies that target a specific genetic mutation found in the tumor, regardless of tumor histology. This emerging trend raises a number of key questions for the industry.

If it's true that a picture is worth a thousand words, the same can be said for numbers.  For any healthcare executive, a look at relevant statistics can be revealing. Here are some of the top stats to know.

Researchers and scientists continue to develop and test new treatments for these fatal conditions. Here’s a look at some major developments in these areas.

When it comes to promising areas in the treatment of lymphoma and other blood cancers, gene therapy may be at the top of the list. Here’s why.

Two oncology practices have wish list items for payers. Find out what they are.

In this era of precision oncology and targeted therapies for cancer, it’s even more important to include different populations when doing clinical trials. Here are three effective strategies.

Researchers say two new related study findings represent a potential new way to identify pancreatic cancer at an earlier stage. Read more.

FDA’s approval of an expanded indication for a prostate cancer drug could net 2 pharmaceutical manufacturers billions of dollars.

Pharma makers are voluntarily recalling several drugs containing this active ingredient, used to treat high blood pressure and heart failure, since they may contain a carcinogen.

A pharma maker is under fire for raising prices on its cancer drugs. Meanwhile, there were two major cancer drug approvals in June. Here are the top 3 cancer news articles in the past month.

Gwen Nichols, MD, chief medical officer of the Leukemia & Lymphoma Society, offers a quick overview of current developments as well as a look forward.

What does team-based cancer care done right look like? Here are two real-word models worth emulating.